Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD
Abstract Gastroesophageal reflux disease (GERD) is a prevalent global condition, affecting 18.1–27.8% of North Americans and 6.3–18.3% of the Thai population. While proton pump inhibitors (PPIs) are the first-line treatment, only about one-third of patients achieve adequate symptom control. Alginate...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-13400-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333571196551168 |
|---|---|
| author | Kawin Tangvoraphonkchai Witsarut Manasirisuk Tanya Apichatvullop Supatra Srikhajonjit Manoon Mitpracha Pattarakorn Promsen Nutchanun Preechakawin Khaimook Onthaisong |
| author_facet | Kawin Tangvoraphonkchai Witsarut Manasirisuk Tanya Apichatvullop Supatra Srikhajonjit Manoon Mitpracha Pattarakorn Promsen Nutchanun Preechakawin Khaimook Onthaisong |
| author_sort | Kawin Tangvoraphonkchai |
| collection | DOAJ |
| description | Abstract Gastroesophageal reflux disease (GERD) is a prevalent global condition, affecting 18.1–27.8% of North Americans and 6.3–18.3% of the Thai population. While proton pump inhibitors (PPIs) are the first-line treatment, only about one-third of patients achieve adequate symptom control. Alginate-based medications in combination with PPIs have shown promise, but the comparative effectiveness of generic versus original alginates remains unexplored. To compare the effectiveness of generic alginate (ONE GERD) versus original alginate (Gaviscon Dual Action Suspension) in combination with PPIs for treating GERD symptoms in patients who failed standard PPI therapy.This multicenter prospective randomized controlled non-inferiority trial included 48 patients who failed standard-dose PPI treatment. Patients were randomized to receive either generic or original alginate four times daily for 28 days. Treatment response was evaluated using the Reflux Disease Questionnaire (RDQ) at days 7 and 28. At day 7, both groups showed identical response rates of 45.83%. By day 28, response rates increased to 54.17% for generic alginate and 70.83% for original alginate (p = 0.23). Total RDQ scores and symptom-free rates showed no significant differences between groups at both time points. Adverse event rates were comparable (16.67% vs. 8.33%, p = 0.66). Analysis of specific symptoms (heartburn, chest pain, and regurgitation) revealed similar improvements in both groups throughout the study period. This study provides evidence supporting the therapeutic equivalence of the generic alginate (ONE GERD) to the original formulation (Gaviscon Dual Action Suspension) in treating symptoms for patients with GERD who have failed PPI therapy. Crucially, the comparable efficacy and safety, coupled with the inherent lower cost of generic medications, suggest significant economic benefits and the potential for wider patient access to effective GERD management. This makes generic alginate a viable and attractive alternative in clinical practice, particularly in resource-limited settings or for patients facing financial constraints, thereby contributing to more equitable healthcare solutions without compromising therapeutic outcomes. |
| format | Article |
| id | doaj-art-cf9ee0ae60bd44eb882ea3d481cde3fd |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-cf9ee0ae60bd44eb882ea3d481cde3fd2025-08-20T03:45:48ZengNature PortfolioScientific Reports2045-23222025-08-011511910.1038/s41598-025-13400-wComparable efficacy of generic and original alginate for symptom control in PPI-refractory GERDKawin Tangvoraphonkchai0Witsarut Manasirisuk1Tanya Apichatvullop2Supatra Srikhajonjit3Manoon Mitpracha4Pattarakorn Promsen5Nutchanun Preechakawin6Khaimook Onthaisong7Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen UniversityDivision of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen UniversityDepartment of Medicine, Khon Kaen HospitalDepartment of Medicine, Khon Kaen HospitalDepartment of Medicine, Khon Kaen HospitalDivision of Gastroenterology and Hepatology, Department of Medicine, Kalasin HospitalDivision of Gastroenterology and Hepatology, Department of Medicine, Pathum Thani HospitalNursing Department, Faculty of Medicine, Srinagarind Hospital, Khon Kaen UniversityAbstract Gastroesophageal reflux disease (GERD) is a prevalent global condition, affecting 18.1–27.8% of North Americans and 6.3–18.3% of the Thai population. While proton pump inhibitors (PPIs) are the first-line treatment, only about one-third of patients achieve adequate symptom control. Alginate-based medications in combination with PPIs have shown promise, but the comparative effectiveness of generic versus original alginates remains unexplored. To compare the effectiveness of generic alginate (ONE GERD) versus original alginate (Gaviscon Dual Action Suspension) in combination with PPIs for treating GERD symptoms in patients who failed standard PPI therapy.This multicenter prospective randomized controlled non-inferiority trial included 48 patients who failed standard-dose PPI treatment. Patients were randomized to receive either generic or original alginate four times daily for 28 days. Treatment response was evaluated using the Reflux Disease Questionnaire (RDQ) at days 7 and 28. At day 7, both groups showed identical response rates of 45.83%. By day 28, response rates increased to 54.17% for generic alginate and 70.83% for original alginate (p = 0.23). Total RDQ scores and symptom-free rates showed no significant differences between groups at both time points. Adverse event rates were comparable (16.67% vs. 8.33%, p = 0.66). Analysis of specific symptoms (heartburn, chest pain, and regurgitation) revealed similar improvements in both groups throughout the study period. This study provides evidence supporting the therapeutic equivalence of the generic alginate (ONE GERD) to the original formulation (Gaviscon Dual Action Suspension) in treating symptoms for patients with GERD who have failed PPI therapy. Crucially, the comparable efficacy and safety, coupled with the inherent lower cost of generic medications, suggest significant economic benefits and the potential for wider patient access to effective GERD management. This makes generic alginate a viable and attractive alternative in clinical practice, particularly in resource-limited settings or for patients facing financial constraints, thereby contributing to more equitable healthcare solutions without compromising therapeutic outcomes.https://doi.org/10.1038/s41598-025-13400-wGastroesophageal reflux diseaseGeneric alginateOriginal alginateProton pump inhibitorsReflux disease questionnaire |
| spellingShingle | Kawin Tangvoraphonkchai Witsarut Manasirisuk Tanya Apichatvullop Supatra Srikhajonjit Manoon Mitpracha Pattarakorn Promsen Nutchanun Preechakawin Khaimook Onthaisong Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD Scientific Reports Gastroesophageal reflux disease Generic alginate Original alginate Proton pump inhibitors Reflux disease questionnaire |
| title | Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD |
| title_full | Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD |
| title_fullStr | Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD |
| title_full_unstemmed | Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD |
| title_short | Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD |
| title_sort | comparable efficacy of generic and original alginate for symptom control in ppi refractory gerd |
| topic | Gastroesophageal reflux disease Generic alginate Original alginate Proton pump inhibitors Reflux disease questionnaire |
| url | https://doi.org/10.1038/s41598-025-13400-w |
| work_keys_str_mv | AT kawintangvoraphonkchai comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT witsarutmanasirisuk comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT tanyaapichatvullop comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT supatrasrikhajonjit comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT manoonmitpracha comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT pattarakornpromsen comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT nutchanunpreechakawin comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd AT khaimookonthaisong comparableefficacyofgenericandoriginalalginateforsymptomcontrolinppirefractorygerd |